From Name:
From Email:
To Name:
To Email:

Optional Message:

Biogen's risky Alzheimer's odyssey raises prospects for new biotech deals

from FierceBiotech

In big biopharma land, many CEOs like to see a blend of high-risk breakthrough drugs with megablockbuster potential and a few relatively low-risk projects in the late-stage pipeline. But following a swift elimination of some 880 jobs, Biogen CEO George Scangos and his team are now focused primarily on two home run swings in an R&D game that will take years to play out. And that has analysts betting Biogen will start doing some late-stage biotech deals or face continued speculation that the big biotech will become a target itself. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063